Muscle Is Not Just an Aesthetic Concern. It Is Your Body's Primary Metabolic Organ.

What Is Sarcopenia and Why Does It Matter?

Sarcopenia is the progressive loss of muscle mass and strength with age. After age 30, most adults lose 3 to 8% of muscle mass per decade, and this accelerates sharply after 60. But sarcopenia's clinical significance extends far beyond appearance. Muscle is the body's largest metabolic organ: 80 to 90% of post-meal glucose clearance depends on muscle GLUT4 transporters, making declining muscle mass one of the primary drivers of insulin resistance. Muscle is also the body's largest producer of myokines, including irisin, which crosses the blood-brain barrier and activates BDNF receptors in the brain. When muscle mass falls, metabolic rate drops, insulin resistance worsens, inflammatory tone rises, and cognitive protection diminishes.

Bone density loss follows a parallel trajectory, driven by the same hormonal environment. The primary drivers of muscle protein synthesis, including testosterone, IGF-1, and growth hormone, decline progressively with age while myostatin (the body's brake on muscle growth) increases. Simultaneously, elevated inflammatory cytokines including TNF-a and IL-6 activate the ubiquitin-proteasome pathway, the molecular machinery that breaks down muscle proteins, producing net catabolism even with adequate protein intake and exercise. Bone remodeling follows the same hormonal environment: when it deteriorates, osteoclast activity outpaces osteoblast activity and bone density falls.

Who the Muscle and Bone Protocol Is For

This protocol is built for patients who are dealing with one or more of the following:

• Declining muscle mass, strength, or exercise performance over the past one to five years despite active effort
• Bone density concerns, osteopenia, or osteoporosis alongside muscle loss or hormonal decline
• Slow recovery from exercise, injury, or physical stress suggesting impaired muscle repair biology
• Interest in peptide or GH secretagogue therapy to optimize anabolic signaling alongside resistance training

How the Muscle and Bone Protocol Works

The baseline panel for this protocol includes sex hormone panel (testosterone, IGF-1), inflammatory markers, Vitamin D, body composition analysis, bone density markers where indicated, and nutritional assessment (protein intake, CoQ10, magnesium). The protocol moves through three stages targeting anabolic signaling, inflammatory muscle catabolism, and bone remodeling simultaneously.

What the Protocol May Include: creatine monohydrate, the most extensively evidence-backed supplement for muscle building with hundreds of published RCTs; omega-3 fatty acids at therapeutic dose for post-exercise inflammatory resolution and muscle protein catabolism reduction; HMB (beta-hydroxy beta-methylbutyrate) specifically targeting the ubiquitin-proteasome muscle breakdown pathway that protein and creatine cannot address; calcium and Vitamin D3+K2 for bone mineral matrix and muscle cell receptor signaling; and ashwagandha for cortisol reduction (cortisol is the primary catabolic hormone activating the muscle breakdown pathway). As the protocol advances, injectable vitamins at the clinic deliver Vitamin D for muscle cell receptor signaling, injectable magnesium for protein synthesis enzyme cofactors and GH pulse support during deep sleep, carnitine for mitochondrial fatty acid transport during training, and injectable zinc for testosterone synthesis and collagen enzyme activity. Stage 3 adds peptide therapy including CJC-1295/Ipamorelin or Sermorelin at bedtime to amplify the nocturnal GH pulse driving satellite cell activation and osteoblast activity; Follistatin to inhibit myostatin, the primary molecular brake on muscle growth; BPC-157 for angiogenesis in adapting musculoskeletal tissue; and IGF-1 for direct anabolic signaling through the PI3K/Akt/mTOR pathway.

Stage 1 (Pathway) establishes the supplement foundation addressing the primary drivers: anabolic substrate, catabolism reduction, and cortisol. Stage 2 (Roadmap) adds injectable delivery at the clinic for therapeutic hormone and connective tissue support. Stage 3 (Atlas) is the complete protocol for patients with significant sarcopenia, bone loss, or those seeking the most comprehensive anabolic and regenerative support.